The therapeutic antibody sacituzumab induces trophoblast cell-surface antigen-2 conformational rearrangement
Structure · 2026
DOI: 10.1016/j.str.2025.11.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Structure, 2026. Verfasst von Ryan Ferrao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences Inc., Structural Biology and Chemistry, 333 Lakeside Dr., Foster City, CA 94404, USA. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Antibodies, Monoclonal, Humanized, Cell Adhesion Molecules, Camptothecin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Institutes of Health, National Institute of General Medical Sciences, Howard Hughes Medical Institute.
Abstract (Originalsprache)
Sacituzumab govitecan (SG) is a therapeutic antibody-drug conjugate globally approved for the treatment of breast cancer. SG targets the trophoblast cell-surface antigen-2 (Trop2) at the surface of cancer cells to deliver the cytotoxic topoisomerase I inhibitor SN-38 to the tumor microenvironment. SN-38 is covalently linked to the humanized monoclonal antibody (mAb) sacituzumab via a hydrolyzable linker. Here, we describe the 1.56-Å X-ray crystal structure and stoichiometry of the human Trop2 ectodomain in complex with a sacituzumab (hRS7) antigen-binding Fab fragment. The complex reveals a 2:2 stoichiometry where two sacituzumab Fabs bind across the two Trop2 dimer subunits, inducing a conformational change compared to the apo-structure. Cryo-electron microscopy (cryoEM) and size-exclusion chromatography in combination with multi-angle light scattering (SEC-MALS) analysis of the intact sacituzumab mAb bound to the Trop2 ECD reveals a complex whereby sacituzumab engages two Trop2 dimers in a 2:4 stoichiometry.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gilead Sciences Inc., Structural Biology and Chemistry, 333 Lakeside Dr., Foster City, CA 94404, USA.
- Gilead Sciences Inc., Protein Therapeutics, 333 Lakeside Dr., Foster City, CA 94404, USA.
- Gilead Sciences Inc., Oncology, 333 Lakeside Dr., Foster City, CA 94404, USA.
- Gilead Sciences Inc., Biologics Analytical Operations, 4010 Ocean Ranch Blvd., Oceanside, CA 92056, USA.
- Gilead Sciences Inc., Biologics Analytical Operations, 4010 Ocean Ranch Blvd., Oceanside, CA 92056, USA. Electronic address: alexandre.ambrogelly@gilead.com.
- Gilead Sciences Inc., Structural Biology and Chemistry, 333 Lakeside Dr., Foster City, CA 94404, USA. Electronic address: eric.lansdon@gilead.com.
Förderung
- National Institutes of Health
- National Institute of General Medical Sciences
- Howard Hughes Medical Institute
- Office of Science
Zitieren
APA
Ferrao, R., Zhang, J., Chou, C. C., Nieto, A., Langeslay, D., Chatterjee, M., Jin, D., Hung, M., Scott, I., Nagel, M., Xing, W., Letarte, S., Wang, J., Ambrogelly, A., & Lansdon, E. B. (2026). The therapeutic antibody sacituzumab induces trophoblast cell-surface antigen-2 conformational rearrangement. Structure. https://doi.org/10.1016/j.str.2025.11.002
Vancouver
Ferrao R, Zhang J, Chou CC, Nieto A, Langeslay D, Chatterjee M, et al. The therapeutic antibody sacituzumab induces trophoblast cell-surface antigen-2 conformational rearrangement. Structure. 2026. doi:10.1016/j.str.2025.11.002
BibTeX
@article{Ferrao2026,
author = {Ferrao, Ryan and Zhang, Jinjin and Chou, Chih-Chien and Nieto, Anthony and Langeslay, Derek and Chatterjee, Moon and Jin, Debi and Hung, Magdeleine and Scott, Ian and Nagel, Mark and Xing, Weimei and Letarte, Simon and Wang, Jenny and Ambrogelly, Alexandre and Lansdon, Eric B},
title = {The therapeutic antibody sacituzumab induces trophoblast cell-surface antigen-2 conformational rearrangement},
journal = {Structure},
year = {2026},
doi = {10.1016/j.str.2025.11.002}
}
EUVIMED